2007

,

Effects of genetic polymorphism of CYP2C9 on the pharmacokinetics of lornoxicam in healthy Korean subjects

2006

,

MDR1 polymorphism significantly affects th pharmacokinetics of losartan

2006

,

CYP2C9*3 and *13 alleles were associated with the decreased metabolism of losartan

2005

,

Effects of CYP2C9 and MDR1 polymorphism on the pharmacokinetics of angiotensinⅡ receptor antagonists